As of June 16, 2025, Amryt Pharma PLC (AMYT.L) reports a Gross Margin of 3481.68%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Amryt Pharma PLC's Gross Margin
Over recent years, Amryt Pharma PLC's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2020-12-31 | 3481.68% |
| 2019-12-31 | 33.36% |
| 2018-12-31 | 63.35% |
| 2017-12-31 | 57.95% |
| 2016-12-31 | 56.62% |
This steady improvement highlights how Amryt Pharma PLC manages its operational efficiency and pricing power over time.
Comparing Amryt Pharma PLC's Gross Margin to Peers
To better understand Amryt Pharma PLC's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Amryt Pharma PLC (AMYT.L) | 3481.68% |
| Ovoca Bio PLC (OVB.L) | 7775.20% |
| Infant Bacterial Therapeutics AB (IBT B.ST) | 7775.20% |
| Corline Biomedical AB (CLBIO.ST) | 137.50% |
| Nutex Befektetesi Nyrt (NUTEX.BD) | 100.00% |
| Hyloris Pharmaceuticals SA (HYL.BR) | 97.32% |
Compared to its competitors, Amryt Pharma PLC's Gross Margin is among the highest compared to peers, indicating superior product pricing power or cost efficiency in production.